10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Monday, March 12, 2012

RPG Life Sciences Ltd:Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger

Scripscan:RPG Life Sciences Ltd

Story:RPG Life Sciences Limited develops, manufactures, and markets a range of branded formulations, generics, and bulk drugs in India. It offers pharmaceuticals formulations, including anti-diarrhoeal products and other products, such as aldactone, naprosyn, tricaine, serenace, and spiromide. The company also provides various products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant, and nephrology segments. In addition, it manufactures active pharmaceutical ingredients, finished dosage forms, and generic formulations, as well as medications for critical and chronic ailments. The company also exports its products primarily to Europe, Latin America, Africa, Australia, the Commonwealth of Independent States, and south east Asian countries. It was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited on February 2008.Last fiscal in terms of its API, it has been a star performer, the top-line has grown 23%, it has grown from Rs 39 crores up to almost upto Rs 49 crore. It had a wonderful performance in terms of PAT. From about, break evens it has moved to profitability of Rs 5-5.2 crore. So, bulk drugs through new product launches and geographical expansion is what it focused in during the year.The generics division has done well too,it has grown 12%. The bottom-line has been flat.The company sold higher into the markets of Canada as well as the European Union.Its investing strongly into development of its product portfolio and therefore a flat bottom-line.In terms of formulations, it has grown during the year at 17%, it has grown faster than pharma market. This is a business that the company has been investing very strongly. In terms of increasing the field force,rpg life has increased the field force almost by about 210 people it is now upto 550. In terms of expansion of the product portfolio, the company launched almost 24 new products with 44 dosage forms.The mangament expects to grow stronger than the market this year,top-line should be 15% up and bottom-line around 18% up.Going further, the company is expected to maintain this growth rate for some more years.A hold at present levels.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner